WEBULL
News
MENS
2.440
+3.83%
0.090
Weekly Report: what happened at MENS last week (0302-0306)?
Weekly Report · 1d ago
Weekly Report: what happened at MENS last week (0223-0227)?
Weekly Report · 03/02 09:05
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 02/25 21:07
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 02/23 17:05
Weekly Report: what happened at MENS last week (0216-0220)?
Weekly Report · 02/23 09:05
Weekly Report: what happened at MENS last week (0209-0213)?
Weekly Report · 02/16 09:05
Jyong Biotech Completes Phase II Trial For MCS-8, Expands Commercial Presence In Asia
Benzinga · 02/12 13:55
Jyong issues strategic corporate update, completes Phase II trial for MCS-8
TipRanks · 02/12 13:35
Jyong Biotech Reports Positive Phase II Results for MCS-8 in Prostate Cancer Prevention and Metabolic Health
Reuters · 02/12 13:30
Weekly Report: what happened at MENS last week (0202-0206)?
Weekly Report · 02/09 09:05
Jyong Biotech Appoints Veteran Capital Markets Executive Wei Zhang as Chief Financial Officer
TipRanks · 02/06 21:59
Jyong Biotech Ltd. Appoints Wei Zhang as Chief Financial Officer
Reuters · 02/06 21:31
Weekly Report: what happened at MENS last week (0126-0130)?
Weekly Report · 02/02 09:05
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer
Reuters · 01/30 18:38
BUZZ-U.S. STOCKS ON THE MOVE-Charter Communications, Western Digital, Regeneron
Reuters · 01/30 15:42
Jyong Biotech Announces Updated Statistical Analyses For Key Blood Biochemical Markers From Phase II Clinical Trial Of MCS-8 Conducted In Taiwan
Benzinga · 01/30 13:45
Jyong Biotech Reports Phase II Trial Results Showing MCS-8 Lowers Cholesterol and May Prevent Prostate Cancer
Reuters · 01/30 13:30
JYONG BIOTECH LTD - MCS-8 SHOWS 27.3% REDUCTION IN PROSTATE CANCER INCIDENCE
Reuters · 01/30 13:30
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
Barchart · 01/30 07:30
Weekly Report: what happened at MENS last week (0119-0123)?
Weekly Report · 01/26 09:05
More
Webull provides a variety of real-time MENS stock news. You can receive the latest news about Jyong Biotech Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About MENS
Jyong Biotech Ltd is a Taiwan-based science-driven biotechnology company. The Company is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The Company has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.